The world's largest peptide therapeutics company
Novo Nordisk is the Danish pharmaceutical giant behind Ozempic, Wegovy, and Rybelsus — all forms of semaglutide, a GLP-1 receptor agonist peptide. Founded in 1923 to commercialize insulin, Novo has become the most valuable company in Europe on the back of the GLP-1 obesity revolution. Its upcoming CagriSema combination and next-generation amycretin pipeline target the next wave of weight-loss peptides.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Ozempic (semaglutide) | Type 2 Diabetes | FDA Approved | GLP-1 RA |
| Wegovy (semaglutide) | Obesity | FDA Approved | GLP-1 RA |
| Rybelsus (oral semaglutide) | Type 2 Diabetes | FDA Approved | Oral GLP-1 RA |
| CagriSema | Obesity | Phase 3 | GLP-1 + amylin |
| Amycretin | Obesity | Phase 2 | GLP-1 + amylin dual agonist |
